Patents Examined by John M Mauro
  • Patent number: 11834461
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: December 5, 2023
    Assignee: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen, Blake Daniels, Craig Stivala
  • Patent number: 11834460
    Abstract: The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: December 5, 2023
    Inventors: Craig M. Crews, George Burslem, Philipp M. Cromm, Saul Jaime-Figueroa, Momar Toure
  • Patent number: 11834428
    Abstract: A method for preparing dihydromyricetin nanocrystals includes: uniformly dispersing dihydromyricetin in a good solvent to obtain a dihydromyricetin solution; uniformly dispersing a precipitator and a stabilizer in water to obtain a mixed solution, and then adding the dihydromyricetin solution into the mixed solution and mixing uniformly under a stirring condition to obtain a dihydromyricetin nanocrystal solution; and drying the dihydromyricetin nanocrystal solution to obtain the dihydromyricetin nanocrystals. The method for preparing the dihydromyricetin nanocrystals by an anti-solvent method is simple and easy to implement, low in cost, good in nanocrystal stability, small in organic solvent consumption, and safe and environment-friendly in preparation process.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: December 5, 2023
    Inventors: Yang Kong, ChangZhao Wang, Bin Tian, Fang Lin, Zihao Li
  • Patent number: 11827617
    Abstract: The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse/dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson's disease.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: November 28, 2023
    Assignee: Astraea Therapeutics, LLC
    Inventors: Nurulain Zaveri, V. Blair Journigan
  • Patent number: 11807647
    Abstract: Disclosed is a crystal form of a hepatitis B surface antigen inhibitor and a preparation method, and an application of the crystal form in the preparation of the hepatitis B surface antigen inhibitor.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: November 7, 2023
    Inventors: Zhe Cai, Fei Sun, Charles Z. Ding
  • Patent number: 11807649
    Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: November 7, 2023
    Assignee: EnLiven Therapeutics, Inc.
    Inventors: Joseph P. Lyssikatos, Samuel Kintz, Li Ren, Qiang Su
  • Patent number: 11802129
    Abstract: The present subject matter involves novel pyrido[3,4-b]indol-1-one compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3,4-b]indol-1-one compounds are useful as anticancer and/or antitumor agents.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: October 31, 2023
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 11787803
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: October 17, 2023
    Assignee: Forma Therapeutics, Inc.
    Inventors: Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
  • Patent number: 11779565
    Abstract: This invention provides small organic molecules useful as therapeutics of neurodegenerative diseases. Small organic molecules that act as inhibitors of bone morphogenetic proteins (BMPs) are useful in the treatment of neuroinflammatory disorders, in particular multiple sclerosis.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: October 10, 2023
    Inventors: Arnon Karni, Karin Bernadet Fainberg
  • Patent number: 11780834
    Abstract: Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: October 10, 2023
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Cheol Keun Chung, Jie Xu, Hans Iding, Kyle Clagg, Michael Dalziel, Alec Fettes, Francis Gosselin, Ngiap-Kie Lim, Andrew McClory, Haiming Zhang, Paroma Chakravarty, Karthik Nagapudi, Sarah Robinson
  • Patent number: 11779577
    Abstract: This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: October 10, 2023
    Inventors: Hakon Hakonarson, Charily Kao
  • Patent number: 11773075
    Abstract: The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: October 3, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte
  • Patent number: 11767330
    Abstract: The present disclosure features citrate salts and pharmaceutical compositions useful for the treatment of BAF complex-related disorders. Also disclosed are methods for preparing compounds.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: September 26, 2023
    Inventors: Chong-Hui Gu, Joshua D. Waetzig
  • Patent number: 11767312
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Grant
    Filed: April 5, 2023
    Date of Patent: September 26, 2023
    Assignee: GENENTECH, INC.
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • Patent number: 11766443
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: September 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Marina Kristina Willwacher, Juergen Prestle, Ferenc Kontes, Leo Thomas, Christofer Siegfried Tautermann, Dieter Wiedenmayer
  • Patent number: 11767320
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: September 26, 2023
    Inventors: Taisheng Huang, Xiaozhao Wang, Wenqing Yao
  • Patent number: 11766444
    Abstract: The present invention relates to a novel use for HDL-ApoM-S1P (a high density lipoprotein in which apolipoprotein M is impregnated with sphingosine-1-phosphate), and more particularly, to using HDL-ApoM-S1P to prevent, improve, or treat degenerative brain disorders (in particular, Alzheimer's disease), cognitive disorders, learning disabilities, and memory disorders, and using HDL-ApoM-S1P to improve cognitive ability, learning ability, and memory. The HDL-ApoM-S1P according to the present invention not only alleviates neuroinflammation but also significantly exhibits improvement effects of cognitive disorder, learning disability, and memory disorder with respect to individuals suffering from degenerative brain disorders (in particular, Alzheimer's disease), and exhibits an effect of greatly reducing amyloid beta and tau deposition. Moreover, increased HDL-ApoM-S1P in the body also has an excellent effect of improving the cognitive, learning, and memory abilities of non-disabled individuals.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: September 26, 2023
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Jae Sung Bae, Hee Kyung Jin, Ju Youn Lee, Min Hee Park
  • Patent number: 11753395
    Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: September 12, 2023
    Inventors: Xiaohu S. Ouyang, Toufike Kanouni, John S. Tyhonas, Jason M. Cox, Robert S. Kania
  • Patent number: 11746115
    Abstract: Solid forms including 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one and a dihydroxybenzoic acid selected from 2,5-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid are provided, as well as pharmaceutical compositions including the solid forms, methods for using the solid forms in treating cancer patients, and methods of making the solid forms.
    Type: Grant
    Filed: August 12, 2022
    Date of Patent: September 5, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Yizheng Cao
  • Patent number: 11739101
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: August 29, 2023
    Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.
    Inventors: Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell